Product details
Background：Anselamimab (CAEL-101) a humanized IgG1-κ anti-Amyloid fibrils antibody targeting to serum amyloid A1 (SAA1).
• Overexpression of serum amyloid a 1 induces depressive-like behavior in mice., PMID:27608955
• Pathogenic serum amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic non-pathogenic SAA2.2., PMID:23223242
• Serum amyloid A levels are associated with polymorphic variants in the serum amyloid A 1 and 2 genes., PMID:30852808
• Large-scale isotype-specific quantification of Serum amyloid A 1/2 by multiple reaction monitoring in crude sera., PMID:22300576
• Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis., PMID:18815155
• Diversity and complexity of the mouse Saa1 and Saa2 genes., PMID:24521869
• The role of PPAR activation during the systemic response to brain injury., PMID:25994490
• Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A., PMID:20890286
• Hematological and acute-phase responses to diet-induced obesity in IL-6 KO mice., PMID:21996012
• Clustering of six human 11p15 gene homologs within a 500-kb interval of proximal mouse chromosome 7., PMID:7698755
